Recombinant Human TRAIL R1 (C-6His）

Description

EnkiLife provides the Recombinant Human TRAIL R1 (C-6His） protein,aslo know as APO2,CD261 antigen,CD261,cytotoxic TRAIL receptor,DR4,TNF-related apoptosis-inducing ligand receptor 1,TNFRSF10A,TRAIL-R1,TRAILR1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human TRAIL R1 is produced by our Mammalian expression system and the target gene encoding Ala24-Asn239 is expressed with a 6His tag at the C-terminus.Accession:O00220. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:23.7 KDa. Background:Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) is also known as TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), Death receptor 4 (DR4), CD261 and APO2, which belongs to TNF superfamily. TNFRSF10A / DR4 is widely expressed and high levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells. APO2 / TNFRSF10A is receptor for the cytotoxic ligand TNFSF10 / TRAIL. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF1/TRAIL), and thus transduces cell death signal and induces cell apoptosis. TRAIL R1 can promote the activation of NF-kappa-B. TRAIL R1/CD261/TNFRSF1A induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types.